Literature DB >> 22356134

Straightforward assembly of phenylimidazoquinoxalines via a one-pot two-step MCR process.

Fabio De Moliner1, Christopher Hulme.   

Abstract

An efficient multicomponent-based methodology providing a new entry into a medicinally important complex heterocyclic core is presented. The strategy is very general and able to endow target compounds with the highest possible number of diversity points. Notably, four new chemical bonds and two aromatic rings are formed in a one-pot fashion.
© 2012 American Chemical Society

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22356134      PMCID： PMC3311158          DOI： 10.1021/ol3003282

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  25 in total

Review 1.  Target-oriented and diversity-oriented organic synthesis in drug discovery.

Authors:  S L Schreiber
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

Review 2.  "Multi-component reactions : emerging chemistry in drug discovery" 'from xylocain to crixivan'.

Authors:  Christopher Hulme; Vijay Gore
Journal:  Curr Med Chem       Date:  2003-01       Impact factor: 4.530

3.  The use of the Ugi four-component condensation.

Authors:  Stefano Marcaccini; Tomás Torroba
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  Two step syntheses of fused quinoxaline-benzodiazepines and bis-benzodiazepines.

Authors:  Zhigang Xu; Justin Dietrich; Arthur Y Shaw; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2010-08-25       Impact factor: 2.415

Review 5.  Beyond Ugi and Passerini reactions: multicomponent approaches based on isocyanides and alkynes as an efficient tool for diversity oriented synthesis.

Authors:  Fabio De Moliner; Luca Banfi; Renata Riva; Andrea Basso
Journal:  Comb Chem High Throughput Screen       Date:  2011-11       Impact factor: 1.339

6.  Applications of multicomponent reactions to the synthesis of diverse heterocyclic scaffolds.

Authors:  James D Sunderhaus; Stephen F Martin
Journal:  Chemistry       Date:  2009       Impact factor: 5.236

7.  A new strategy for the construction of the imidazo[1,5-a]quinoxalin-4-one ring system and its application to the efficient synthesis of BMS-238497, a novel and potent Lck inhibitor.

Authors:  Bang-Chi Chen; Rulin Zhao; Mark S Bednarz; Bei Wang; Joseph E Sundeen; Joel C Barrish
Journal:  J Org Chem       Date:  2004-02-06       Impact factor: 4.354

8.  Application of the modified Pictet-Spengler cyclization reaction for the preparation of an imidazopyrazine ring: synthesis of new pyrido- and pyrimido-imidazopyrazines.

Authors:  Sunil Sharma; Bijoy Kundu
Journal:  J Comb Chem       Date:  2009 Jul-Aug

9.  Dipolar cycloaddition of ethyl isocyanoacetate to 3-chloro-2-(methylthio)/2-(methylsulfonyl)quinoxalines: highly regio- and chemoselective synthesis of substituted imidazo[1,5-a]quinoxaline-3-carboxylates.

Authors:  G S M Sundaram; B Singh; C Venkatesh; H Ila; H Junjappa
Journal:  J Org Chem       Date:  2007-06-01       Impact factor: 4.354

Review 10.  Emerging molecular diversity from the intra-molecular Ugi reaction: iterative efficiency in medicinal chemistry.

Authors:  Christopher Hulme; Justin Dietrich
Journal:  Mol Divers       Date:  2009-02-11       Impact factor: 3.364
View more
  3 in total

1.  Aldol reactions in multicomponent reaction based domino pathways: a multipurpose enabling tool in heterocyclic chemistry.

Authors:  Zhigang Xu; Fabio De Moliner; Alexandra P Cappelli; Christopher Hulme
Journal:  Org Lett       Date:  2013-05-29       Impact factor: 6.005

2.  A Van Leusen deprotection-cyclization strategy as a fast entry into two imidazoquinoxaline families.

Authors:  Fabio De Moliner; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2012-08-24       Impact factor: 2.415

3.  MCRs reshaped into a switchable microwave-assisted protocol toward 5-aminoimidazoles and dihydrotriazines.

Authors:  Christan E Bell; Arthur Y Shaw; Fabio De Moliner; Christopher Hulme
Journal:  Tetrahedron       Date:  2014-01-07       Impact factor: 2.457
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.